DB05346ExperimentalSmall molecule
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
- Mechanism
- Curator reviewed
An active ingredients in WL-1002 is civamide which has anticeptic property.The antinociception of civamide is probably mediated two mechanisms: (i) an acute receptor occupancy dependent effect; and (ii) a persistent and receptor independent effect which is initiated by the acute exposure to the drug.
- Primary indication
- Investigated for use/treatment in osteoarthritis and pain (acute or chronic).Curator reviewed
- Code names
- WL-1002
What you can answer from here — as of April 02, 2025
Which companies are running trials of WL-1002, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account